Natera, Inc. $NTRA Holdings Increased by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC boosted its position in Natera, Inc. (NASDAQ:NTRA) by 22.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,770 shares of the medical research company’s stock after purchasing an additional 3,451 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Natera were worth $7,758,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. Diversify Advisory Services LLC purchased a new stake in shares of Natera in the third quarter worth $423,000. Focused Alpha LLC boosted its stake in Natera by 20.6% during the third quarter. Focused Alpha LLC now owns 2,096 shares of the medical research company’s stock valued at $866,000 after buying an additional 358 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in Natera by 10.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 14,324 shares of the medical research company’s stock valued at $5,920,000 after buying an additional 1,317 shares during the period. Abel Hall LLC purchased a new position in Natera during the third quarter worth about $259,000. Finally, Kaufman Rossin Wealth LLC grew its position in Natera by 21.1% during the third quarter. Kaufman Rossin Wealth LLC now owns 1,046 shares of the medical research company’s stock worth $432,000 after buying an additional 182 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Stock Down 2.9%

Shares of Natera stock opened at $401.37 on Friday. Natera, Inc. has a 52-week low of $181.00 and a 52-week high of $437.41. The company has a fifty day moving average of $365.45 and a 200-day moving average of $281.52.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.74) EPS. Analysts predict that Natera, Inc. will post -1.05 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, insider John Fesko sold 6,517 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the completion of the sale, the insider directly owned 197,257 shares in the company, valued at $63,424,043.21. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 1,273 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $413.31, for a total value of $526,143.63. Following the transaction, the chief executive officer directly owned 96,926 shares in the company, valued at $40,060,485.06. This trade represents a 1.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 52,985 shares of company stock valued at $16,119,137. Corporate insiders own 5.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on NTRA. BTIG Research upped their target price on Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Citigroup lifted their price target on Natera from $365.00 to $480.00 and gave the company a “buy” rating in a research report on Tuesday, October 6th. TD Cowen boosted their price objective on Natera from $340.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Royal Bank Of Canada upped their price objective on shares of Natera from $350.00 to $460.00 and gave the stock an “outperform” rating in a research report on Friday, September 25th. Finally, Evercore restated an “outperform” rating and issued a $300.00 price objective on shares of Natera in a research report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and an average price target of $379.20.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.